TITLE:
Combined phosphodiesterase inhibitors in end-stage heart failure: A case presentation
AUTHORS:
Javier Reyna, Julio G. Peguero, Esteban Escolar, Orlando Santana, Gervasio A. Lamas
KEYWORDS:
Heart Failure; Phosphodiesterase Inhibitors
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.3 No.3,
June
4,
2013
ABSTRACT: Heart failure (HF) is the leading cause of morbidity and
mortality and is evolving to epidemic
proportions. Despite pharmacologic advances and device interventions, HF remains
a progressive disease. The phosphodiesterase
inhibitors-3 (PDE3I), and more recently, the phosphodiesterase inhibitors-5
(PDE5I) have been used as part of the treatment in certain patients, however,
such combination has not been studied or reported before.